The Indiana University School of Medicine Neurofibromatosis Clinic in the Department of Neurology is the only clinic for comprehensive care of those with neurofibromatosis in the state of Indiana.
Neurofibromatosis researchers in the Department of Neurology have been leaders in investigating the molecular basis of neurofibromatosis and developing new treatment options based on the work. For example, researchers discovered that the anti-cancer drug Gleevec could be used as a therapy in neurofibromatosis type 1, making it the first effective treatment for the tumors affecting many NF1 patients.
